REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
← catalyst calendarNCT07015905 · readout in 185 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
2,000estimated
Sites
46
Countries
Bulgaria, Hungary, Japan +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-25 | actual | When the study began enrolling |
| Primary completion | 2027-02-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Venous Thromboembolism (VTE)
Interventions
- Drug: REGN7508 — also filed as cenvacibart
- Drug: Apixaban
- Drug: Enoxaparin — also filed as Inhixa
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of the composite endpoint of asymptomatic or symptomatic Venous Thromboembolism (VTE) [including VTE-related death]
measured Through day 12 visit, approximately 14 days
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed